Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CogstateCOGZF -12.06%90 EBIT per Share is $0.08 as of Dec. 2025. GuruFocus rates COGZF with a GF Score™ of 90/100 and a GF Value™ of $1.59 (Fairly Valued). Among 525 Healthcare Providers & Services companies, Cogstate ranks worse than 64.57% on this metric.
Cogstate's EBIT per Share for the
six
months ended in Dec. 2025 was $0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.08.
During the past 12 months, the average EBIT per Share Growth Rate of Cogstate was -4.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 3.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cogstate's EBIT per Share or its related term are showing as below:
COGZF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -160.4 Med: 28.7 Max: 143.8
Current: 3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cogstate was 143.80% per year. The lowest was -160.40% per year. And the median was 28.70% per year.
COGZF's 3-Year EBIT Growth Rate is ranked worse than 64.57% of 525
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs COGZF: 3.00
Cogstate's EBIT for the
six
months ended in Dec. 2025 was $5.35 Mil.
Cogstate (OTCPK:COGZF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cogstate EBIT per Share Related Terms
Cogstate EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cogstate's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogstate (COGZF) has a EBIT per Share of $0.08 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cogstate and its competitors. According to the industry distribution chart, Cogstate ranks #339 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 64.6%.
Is Cogstate's EBIT per Share too high?
Cogstate's current EBIT per Share is $0.08. The Healthcare Providers & Services industry median EBIT per Share is 12.00. Cogstate's value of $0.08 is 99.3% below this industry median. Based on the distribution chart, Cogstate ranks #339 out of 525 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cogstate has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #339 out of 525 companies for EBIT per Share. This places Cogstate in the lower half of its industry. The industry median EBIT per Share is 12.00. Cogstate's value of $0.08 is 99.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current EBIT per Share of $0.08 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cogstate and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current EBIT per Share is $0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (COGZF) is currently considered Fairly Valued. The stock's GF Value™ is $1.59, compared to a current price of $1.75 — trading 10.1% above its estimated fair value. The current EBIT per Share is $0.08 and 99.3% below the Healthcare Providers & Services industry median of 12.00. Cogstate's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cogstate (COGZF), the current EBIT per Share is $0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (COGZF) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of $1.75 is trading 10.1% above its estimated GF Value™ of $1.59.
GuruFocus considers Cogstate to be Fairly Valued.
Key valuation signals for COGZF:
EBIT per Share: $0.08
GF Value™: $1.59 vs. price of $1.75 (10.1% above fair value)
Industry Position: 99.3% below the Healthcare Providers & Services median (#339 of 525)
No single metric tells the full story. See the COGZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
90GF Score
Get the complete analysis for COGZF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGZF has been successfully added to your 
